Pages that link to "Q71135770"

The following pages link to Dose requirements of hydralazine in patients with severe chronic congestive heart failure (Q71135770):

Displaying 26 items.

• Congestive heart failure (Q34101370) (← links)
• Efficacy of felodipine in chronic congestive heart failure: a placebo controlled haemodynamic study at rest and during exercise and orthostatic stress (Q34118763) (← links)
• Which vasodilator drug in patients with chronic heart failure? A randomised comparison of captopril and hydralazine (Q34358252) (← links)
• Vasodilators. A re-evaluation of their role in heart failure (Q35313284) (← links)
• Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations (Q38215916) (← links)
• Effects of cardiovascular disease on pharmacokinetics (Q38378935) (← links)
• Medical therapy and prognosis in chronic heart failure. Lessons from clinical trials. (Q39477465) (← links)
• The treatment of heart failure. A methodological review of the literature (Q39506159) (← links)
• Clinical pharmacokinetics in heart failure. An updated review (Q39557779) (← links)
• The role of vasodilator therapy in the treatment of severe chronic heart failure (Q39764418) (← links)
• Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification (Q40087599) (← links)
• Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism (Q40091787) (← links)
• Vasodilator therapy in chronic congestive heart failure (Q40155609) (← links)
• Clinical pharmacokinetics of hydralazine (Q40333930) (← links)
• Nitrates in the treatment of congestive heart failure (Q40991764) (← links)
• Resistance to isosorbide dinitrate in patients with severe chronic heart failure: Incidence and attempt at hemodynamic prediction (Q41265231) (← links)
• Hemodynamic responses to combined therapy with captopril and hydralazine in patients with severe heart failure (Q42247394) (← links)
• Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure (Q46969882) (← links)
• Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. (Q54465894) (← links)
• Long-term beneficial effects of endralazine, a new arteriolar vasodilator at rest and during exercise capacity in chronic congestive heart failure. (Q54465898) (← links)
• Hemodynamic effects of vasodilators and long-term response in heart failure (Q54474048) (← links)
• Hydralazine therapy in severe chronic heart failure: Inability of radionuclide left ventricular ejection fraction measurement to predict the hemodynamic response (Q54489062) (← links)
• Congestive heart failure (Q70140780) (← links)
• Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure (Q70835217) (← links)
• Variability of plasma hydralazine concentrations in male hypertensive patients (Q70935294) (← links)
• Pharmacokinetics of oral hydralazine in chronic heart failure (Q71142477) (← links)